

## PHARMACOPEIAL DISCUSSION GROUP ACHIEVEMENTS

### Pharmacopeial Discussion Group announces outcome of 2025 expansion round

July 11, 2025

The Pharmacopeial Discussion Group (PDG) is pleased to share the outcome of its latest expansion round.

The initial expansion phase launched in 2022 led, after a successful pilot phase, to the inclusion of the Indian Pharmacopoeia Commission as the first new member of the PDG in 2023. Building on this recent experience, and in order to ensure that any new candidate receives appropriate support, the PDG carefully reviewed its available resources in light of its strategic priorities, deciding to admit one pharmacopoeia during this second phase.

Following a thorough review process and a consensus decision among PDG members, the group is therefore delighted to announce that the Korean Pharmacopoeia has been selected for admission as a **Candidate Participant** ([Framework for the PDG to introduce new members](#)). This decision reflects the quality of the Korean Pharmacopoeia's application and its alignment with the PDG's mission to promote global harmonisation of pharmacopeial standards.

The PDG would like to thank all applicants for their interest and participation in this round and congratulates the Korean Pharmacopoeia on their successful application. The group looks forward to fruitful discussions and harmonisation work with the new Candidate Participant in the coming months.

Contact:

Division of Pharmacopoeia and Standards for Drugs,  
Office of Review Management, PMDA

TEL: +81-(0)3-3506-9431 FAX: +81-(0)3-3506-9445